Physician profile
Collins Kellogg
NPI 1225031255
$2,709.72
in general payments reported to CMS, 2019-2025
26 companies · $706 in 2025
The $706 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $226 · 2021: $114 · 2022: $95.56 · 2023: $397 · 2024: $702 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,805.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $491.67 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $445.50 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Madrigal Pharmaceuticals | $422.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $204.48 | 2024-2025 | Voquezna |
| Abbvie INC. | $121.74 | 2019-2025 | |
| Lilly USA, LLC | $100.00 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $93.84 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Otsuka America Pharmaceutical, INC. | $83.17 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $82.89 | 2020-2025 | Eliquis, Camzyos |
| Pfizer INC. | $69.51 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $62.17 | 2019-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $60.87 | 2023-2025 | |
| Lundbeck LLC | $51.13 | 2024-2025 | Rexulti |
| Amgen INC. | $49.50 | 2023-2025 | Otezla, Repatha, Otezla |
| Abbott Laboratories | $47.81 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45.41 | 2019-2023 | |
| Baxter Healthcare | $44.71 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Dexcom, INC. | $41.04 | 2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $40.34 | 2019-2020 | |
| Boston Scientific Corporation | $28.98 | 2020 | |
| Glaxosmithkline, LLC. | $28.48 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $25.26 | 2025 | Gemtesa |
| Acadia Pharmaceuticals INC | $21.58 | 2022 | |
| Aimmune Therapeutics, INC. | $21.50 | 2024 | |
| Shield Therapeutics INC | $13.90 | 2023 | Accrufer |
| Sunovion Pharmaceuticals INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collins Kellogg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.